Global Congenital Hyperinsulinism Treatment Market Report and Forecast 2023-2031

Global Congenital Hyperinsulinism Market Report and Forecast 2023-2031

Global Congenital Hyperinsulinism Market Outlook

The global congenital hyperinsulinism market size was valued at USD 153.25 million in 2022 and is projected to grow at a CAGR of 4.80% during the forecast period of 2023-2031 to reach a value of USD 223.70 million by 2031. The market growth can be attributed to the rising awareness about the condition and advances in diagnostic and treatment options.

Global Congenital Hyperinsulinism Market: Introduction

Congenital hyperinsulinism is a rare genetic disorder characterized by excessive insulin secretion, leading to hypoglycaemia. The condition primarily affects infants and can cause seizures, developmental delays, and other severe complications if left untreated. The increasing prevalence of congenital hyperinsulinism, along with growing awareness about the condition, is driving the demand for effective diagnostic and treatment options. Technological advancements in genetic testing and imaging techniques, coupled with the development of novel therapeutic approaches, are expected to drive market growth.

Congenital Hyperinsulinism Epidemiology

The exact prevalence of congenital hyperinsulinism is unknown, but the prevalence of congenital hyperinsulinism is estimated to affect approximately 1 in 25,000 to 50,000 live births worldwide. However, this figure may vary across different populations and regions due to differences in genetic factors, demographics, and diagnostic practices. Some specific populations, such as those with consanguineous marriages or certain ethnic groups, may have a higher prevalence of congenital hyperinsulinism.

There are various genetic mutations associated with congenital hyperinsulinism, which can be inherited in an autosomal recessive or autosomal dominant manner. Mutations in genes such as ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, UCP2, and HNF4A have been identified in individuals with congenital hyperinsulinism. These genetic mutations impact the function of pancreatic beta cells, leading to the excessive secretion of insulin and subsequent hypoglycaemia.

Congenital Hyperinsulinism Market Segmentations

The market can be segmented based on diagnosis method, treatment methods, treatment channel, and region:

Market Breakup by Diagnosis Methods

  • Genetic Testing
  • Blood Tests
  • Others
Market Breakup by Treatment Methods
  • Medication
  • Diazoxide
  • Octreotide
  • Glucagon
  • Insulin
  • Others
  • Surgical Treatment
  • Others
Market Breakup by Treatment Channel
  • Private
  • Publics
Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others
Congenital Hyperinsulinism Market Analysis

The global congenital hyperinsulinism market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of congenital hyperinsulinism, rising awareness about the condition, and advances in diagnostic and treatment options. One key driver of growth in the congenital hyperinsulinism market is the increasing prevalence of the condition.

North America currently dominates the global congenital hyperinsulinism market, accounting for a significant share of the global market. The region's large market share is driven by factors such as a higher prevalence of congenital hyperinsulinism, a well-established healthcare infrastructure, and strong investment in research and development. In addition, the growing adoption of advanced diagnostic techniques and novel therapeutic approaches is further driving the growth of the market in North America.

Europe is also a significant market for congenital hyperinsulinism, with countries such as the United Kingdom, Germany, and France leading the way. The region's market growth is driven by factors such as a large population base, increasing awareness of congenital hyperinsulinism, and government initiatives to address rare diseases. Additionally, the region has a well-established healthcare system, which supports the delivery of diagnostic and treatment services.

Asia Pacific is another region that is experiencing significant growth in the congenital hyperinsulinism market. The region's market growth is driven by factors such as a large population base, increasing awareness of congenital hyperinsulinism, and the growing adoption of advanced diagnostic and treatment technologies. In addition, government initiatives to address rare diseases are helping to drive the growth of the market in the region.

Key Players in the Global Congenital Hyperinsulinism Market

The report provides a detailed analysis of the key players involved in the congenital hyperinsulinism market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
  • Eli Lilly
  • Novo Nordisk
  • Novartis AG
  • Rezolute, Inc.
  • Eiger BioPharmaceuticals.
  • Zealand Pharma A/S
  • Hanmi Pharmaceutical Co., Ltd.
  • Crinetics Pharmaceuticals, Inc.
  • AmideBio LLC

*Please Note:* The report will be completed in 7 business days after order confirmation


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Congenital Hyperinsulinism Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Model
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop- out Analysis
7.3 Awareness and Prevention Gaps
8 Global Congenital Hyperinsulinism Treatment Market
8.1 Global Congenital Hyperinsulinism Treatment Market Overview
8.2 Global Congenital Hyperinsulinism Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Historical Congenital Hyperinsulinism Treatment Market Volume (2016-2022)
8.2.1.2 Global Forecast Congenital Hyperinsulinism Treatment Market Volume (2023-2031)
8.2.2 Global Congenital Hyperinsulinism Treatment Market by Diagnosis Method
8.2.2.1 Market Overview
8.2.2.1.1 Blood Test
8.2.2.1.1.1 Genetic Test
8.2.2.1.1.2 Plasma Sugar
8.2.3 Global Congenital Hyperinsulinism Treatment Market by Treatment Method
8.2.3.1 Market Overview
8.2.3.1.1 Drug Therapy
8.2.3.1.1.1 Diazoxide
8.2.3.1.1.2 Octreotide
8.2.3.1.1.3 Glucagon
8.2.3.1.1.4 Others
8.2.3.1.2 Surgery
8.3 Global Congenital Hyperinsulinism Treatment Market by Treatment Channel
8.3.1 Public
8.3.2 Private
8.4 Global Congenital Hyperinsulinism Treatment Market by Region
8.4.1 Market Overview
8.4.1.1 North America
8.4.1.2 Europe
8.4.1.3 Asia Pacific
8.4.1.4 Middle East and Africa
8.4.1.5 Latin America
9 North America Congenital Hyperinsulinism Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Congenital Hyperinsulinism Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Congenital Hyperinsulinism Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Congenital Hyperinsulinism Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Congenital Hyperinsulinism Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Congenital Hyperinsulinism Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Market Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Eli Lilly
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Novo Nordisk
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Novartis AG
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Rezolute, Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Eiger BioPharmaceuticals.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Zealand Pharma A/S
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Hanmi Pharmaceutical Co., Ltd.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Crinetics Pharmaceuticals, Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 AmideBio LLC
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
16 Global Congenital Hyperinsulinism Treatment Market- Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings